Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €40.80 EUR
Change Today -0.15 / -0.37%
Volume 71.9K
DIA On Other Exchanges
Symbol
Exchange
BrsaItaliana
Stuttgart
OTC US
OTC US
As of 11:30 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

diasorin spa (DIA) Snapshot

Open
€40.90
Previous Close
€40.95
Day High
€41.21
Day Low
€40.16
52 Week High
04/7/15 - €42.78
52 Week Low
08/8/14 - €26.00
Market Cap
2.3B
Average Volume 10 Days
152.7K
EPS TTM
€1.54
Shares Outstanding
55.9M
EX-Date
05/18/15
P/E TM
26.5x
Dividend
€0.60
Dividend Yield
1.35%
Current Stock Chart for DIASORIN SPA (DIA)

Related News

No related news articles were found.

diasorin spa (DIA) Related Businessweek News

No Related Businessweek News Found

diasorin spa (DIA) Details

DiaSorin S.p.A. is engaged in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products for diagnosis of infectious diseases; immunoassays for the management of bone and calcium metabolic related diseases; endocrinology products for endocrine system diseases; such as diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology, bone and calcium metabolic related diseases, hypertension, and oncology; enzyme linked immunosorbent assays; and SPQ serum protein quantification assays. Its immunodiagnostics instruments include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; ETI Max 3000, an automated microtiter plate analyzer; EVOlyzer 2-150/8 with disposable tips; and ELISA washers and readers. The company also offers molecular diagnostic products, including systems, software, kits, reagents, and consumables, such as Bullet Pro to perform extractions from different biological samples as required in big laboratories; LIAISON IXT to extract the nucleic acid from different biological samples and it is used in combination with LIAISON IAM amplification system; and LIAISON IAM to diagnose and monitor various infectious diseases and Onco-hematology parameters. In addition, it provides Middleware DiaLink 3000, a middleware solution. The company sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Founded in 1968

diasorin spa (DIA) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: €705.5K
Senior Corporate Vice President of Commercial...
Total Annual Compensation: €435.7K
Compensation as of Fiscal Year 2013.

diasorin spa (DIA) Key Developments

DiaSorin SpA Reports Group Earnings Results for the Year 2014; Provides Earnings Guidance for the Year 2015

DiaSorin SpA reported group earnings results for the year 2014. For the year, the company reported net profit of EUR 84.1 million, up 1.2% on the year, as sales of chemiluminescent immunoassay (CLIA) diagnostic tools offset lower sales of Vitamin D tests. The company generated revenues of EUR 443.8 million last year, up 2.8% at constant exchange rates, with CLIA sales rising 17% and Vitamin D test sales falling 8.6%. The group's increased sales in Europe, Africa and Asia Pacific also compensated for lower sales in the Americas. Earnings before interest, tax, depreciation and amortisation (EBITDA), however, dropped 1.7% to EUR 160.3 million, on the back of expenses on reorganisation in Norway, France and Italy, higher expenses on research and development (R&D), and costs to boost the molecular business. Free cash flow (FCF) increased by EUR 11.9 million to EUR 91.3 million as of the end of 2014. In view of the 2014 performance, the macroeconomic environment and the diagnostics market in general, the company expects its revenues to rise by between 4% and 5% in 2015 compared with 2014, and EBITDA to also grow by 4-5% at constant exchange rates this year.

DiaSorin S.p.A., 2014 Earnings Call, Mar 03, 2015

DiaSorin S.p.A., 2014 Earnings Call, Mar 03, 2015

DiaSorin S.p.A. to Report Fiscal Year 2014 Results on Mar 03, 2015

DiaSorin S.p.A. announced that they will report fiscal year 2014 results on Mar 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIA:IM €40.80 EUR -0.15

DIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $136.47 USD -1.31
Cepheid $55.65 USD -1.46
ERBA Diagnostics Inc $3.49 USD +0.049
Meridian Bioscience Inc $18.59 USD -0.33
Trinity Biotech PLC $17.49 USD -0.12
View Industry Companies
 

Industry Analysis

DIA

Industry Average

Valuation DIA Industry Range
Price/Earnings 23.6x
Price/Sales 4.5x
Price/Book 4.1x
Price/Cash Flow 24.3x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIASORIN SPA, please visit www.diasorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.